Ascendis Pharma A/S ADR [ASND] stock prices are up 12.96% to $142.49 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ASND shares have gain 13.97% over the last week, with a monthly amount glided 8.30%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ascendis Pharma A/S ADR [NASDAQ: ASND] stock has seen the most recent analyst activity on January 07, 2025, when UBS initiated its Buy rating and assigned the stock a price target of $196. Previously, Oppenheimer upgraded its rating to Outperform on September 05, 2024, and kept the price target unchanged to $180. On June 25, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $175 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $200 on May 31, 2024. Jefferies initiated its recommendation with a Buy and recommended $150 as its price target on December 20, 2023. In a note dated April 05, 2023, Oppenheimer downgraded an Perform rating on this stock.
The stock price of Ascendis Pharma A/S ADR [ASND] has been fluctuating between $111.09 and $161.00 over the past year. Currently, Wall Street analysts expect the stock to reach $213.67 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $142.49 at the most recent close of the market. An investor can expect a potential return of 49.95% based on the average ASND price forecast.
Analyzing the ASND fundamentals
The Ascendis Pharma A/S ADR [NASDAQ:ASND] reported sales of 391.88M for trailing twelve months, representing a surge of 25.27%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.96%, Pretax Profit Margin comes in at -1.27%, and Net Profit Margin reading is -1.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is 2.13 and Total Capital is -1.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-8.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 137.68 points at the first support level, and at 132.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 147.49, and for the 2nd resistance point, it is at 152.49.
Ratios To Look Out For
It’s worth pointing out that Ascendis Pharma A/S ADR [NASDAQ:ASND]’s Current Ratio is 1.17. On the other hand, the Quick Ratio is 0.84, and the Cash Ratio is 0.75. Considering the valuation of this stock, the price to sales ratio is 21.73.
Transactions by insiders
Recent insider trading involved SINGEL STINA, Officer, that happened on Dec 10 ’24 when 2119.0 shares were purchased. Officer, JENSEN MICHAEL WOLFF completed a deal on Dec 10 ’24 to buy 2119.0 shares. Meanwhile, Officer PEDERSEN ANNI LOTTE KIRSTINE S bought 1222.0 shares on Dec 10 ’24.
